Accession Number:

ADA468865

Title:

Improved Wound Healing of Cutaneous Sulfur Mustard Injuries in a Weanling Pig Model

Descriptive Note:

Journal article

Corporate Author:

ARMY MEDICAL RESEARCH INST OF CHEMICAL DEFENSE ABERDEEN PROVING GROUND MD

Report Date:

2006-11-08

Pagination or Media Count:

24.0

Abstract:

OBJECTIVE The objective was to examine the efficacy of several treatment regimens in improving wound healing of cutaneous sulfur mustard HD injuries. METHODS Wound healing studies were conducted in weanling pigs. Superficial dermal HD injuries were debrided at 48 hours post-exposure using an erbium-doped yttrium aluminum garnet ErYAG laser, followed by application of a treatment adjunct. A variety of noninvasive bioengineering methods were conducted during the post-surgical observation period to examine the various cosmetic and functional aspects of the skin. Histopathology was performed at the end of each study 14 or 21 days post-surgery. RESULTS As noted clinically, re-epithelialization was nearly complete by 7 days post-surgery for many of the sites treated with petrolatum and scarlet red dressings. By 21 days, the skin elasticity of the petrolatum-dressed sites was not significantly different from that of sham-exposed skin. Upon dressing removal on post-surgery day 4, the neoepidermis of allograft- and thin film-dressed sites was partially removed, with resultant petechial hemorrhaging. Mean pathology scores for hydro-colloid-dressed sites were significantly lower than those of untreated HD-exposed sites on postsurgery day 14. CONCLUSIONS Care must be taken during bandage changes, and a non-adherent dressing that could be left in place for a longer period of time e.g., 7 days would be beneficial. The use of cultured epithelial allograft material may have a potential role if grown on a completely non-adherent backing and left undisturbed for at least a week. Xeroform Petrolatum and Scarlet Red Ointment dressings are effective and inexpensive treatment adjuncts for HD injuries.

Subject Categories:

  • Medicine and Medical Research
  • Chemical, Biological and Radiological Warfare

Distribution Statement:

APPROVED FOR PUBLIC RELEASE